logo
New Orleans Police Officer Who Shot a Puppy Will Face Trial

New Orleans Police Officer Who Shot a Puppy Will Face Trial

Yahooa day ago

A Louisiana police officer who shot and killed a puppy in 2021 will now face trial, after a lengthy legal battle.
On April 10, 2021, two New Orleans Police Department officers were called to Derek Brown and Julia Barecki-Brown's home after receiving a noise complaint. According to legal documents, as the pair approached the house, one officer, Derrick Burmaster, claimed he made "kissy noises" to attract any dogs. Believing there were no dogs nearby, the officers approached the Brown's house. As they did so, a dog began barking, and Burmaster drew his firearm. While the other officer left the Browns' yard after hearing the barking, Burmaster stayed, and the Brown's two dogs then ran down the stairs of the home and approached the officers.
One of the dogs, a 16-week-old, 22-pound puppy named Apollo approached Burmaster while wagging his tail. Burmaster fired three shots at Apollo, striking the dog in his neck and chest. Hearing gunshots, the Browns came into the yard, and Derek "held Apollo as he died from the gunshot wound," according to the couple's lawsuit.
The couple filed a lawsuit against Burmaster and the City of New Orleans in 2022, alleging that Burmaster unconstitutionally 'seized' Apollo by shooting him. "It is clearly established that an officer cannot shoot a dog in the absence of an objectively legitimate and imminent threat to him or others," the suit reads. "A twenty-two-pound Catahoula puppy, standing less than a foot and a half tall, does not present an objectively legitimate and imminent threat to police officers."
A yearslong legal battle followed. Earlier this year, the United States Court of Appeals for the 5th Circuit ruled against Burmaster's attempt to appeal a lower court's decision that the case could not be thrown out on qualified immunity grounds.
"A reasonable jury could conclude that Burmaster did not reasonably believe that Bruno, a small puppy who was wagging his tail shortly before the shooting, posed a threat," the decision reads. "A reasonable jury could further conclude that Burmaster did not reasonably believe he was in imminent danger, based on Bruno's [sic] size, Burmaster's ability to exit the yard, and the availability of non-lethal tools like the taser and police boots." (The ruling appears to have confused Apollo's name.)
Despite efforts to toss the Browns' suit, the case is now set to go to trial. This is far from the first case of "puppycide," where a police officer has shot a dog that posed no obvious threat to his saftey. Burmaster himself fatally shot another dog in 2012, according to The Associated Press. Earlier this month, another Louisiana police department announced that it was investigating two different incidents in which officers shot dogs. It's not uncommon for puppycide cases to be particularly nonsensical. Last year, a Missouri man sued an officer who shot his 13-pound, deaf and blind Shih Tzu. In 2023, another Missouri family's dog wandered away from their home during a storm. When a neighbor found the dog and called to police for help, the officer shot the dog and threw its body in a ditch, rather than simply returning it to its owners.
"[Police] don't need to be dog trainers," Cynthia Bathurst, the executive director of the animal welfare group Safe Humane, told Reason in 2016. "They just need to know what to look for and defuse or control the situation with the resources available. It's the compassionate and right thing to do. It's better for community relations. And if that doesn't move them, the huge lawsuits should."
The post New Orleans Police Officer Who Shot a Puppy Will Face Trial appeared first on Reason.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting

Yahoo

time9 hours ago

  • Yahoo

MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the 'Court') has fully dismissed the application (CV-25-00743454-00CL) (the 'Application') issued by Apollo Technology Capital Corporation ('Apollo') and Nobul Technologies Inc. (together with Apollo, the 'Applicants') against the Company on May 16, 2025 (the 'Notice'). The Applicants sought an order from the Court, amongst other things, appointing a third-party independent chair to preside over the Annual and Special Meeting of Shareholders of the Company (the 'Meeting') on June 16, 2025. The Applicants argued that MediPharm has a 'design or plan to invalidate proxies' and that the Company had acted improperly warranting the appointment of a third-party independent chair. The Court dismissed the Application in full. In doing so, the Court found that a third-party independent chair was not required in the circumstances as there was no evidence or indication that MediPharm's proposed meeting chair will act unfairly at the Meeting. Regarding the conduct of Apollo's principal, Mr. Regan McGee, the Court found: 'The evidence shows that Mr. McGee has threatened to release a draft press release which, among other things, compared Mr. Pidduck to known serial killers. Press Releases have also been issued by Mr. McGee or the Applicants which accuse MediPharm and the Board of securities fraud, breach of fiduciary duty and running a corrupt election process to entrench themselves. Mr. McGee has threatened to sue the Board by way of a derivative action for breach of fiduciary duty and associated damages because of the rejection of the $3.4 million offer and has commenced a lawsuit against MediPharm, two of its senior officers and directors, as well as the Company's external litigation firm (Tyr LLP) and counsel (James Bunting) which claimed $50 million in damages. Mr. McGee, repeated the allegations set out in the lawsuit in the Dissident Circular and then abandoned and withdrew the claim against Tyr LLP and Mr. Bunting, and agreed to terms of settlement that included a declaration by Mr. McGee that Tyr LLP and Mr. Bunting are not in a conflict of interest in acting for MediPharm, that they had not misused confidential information, that Mr. McGee would not disparage Mr. Bunting or Tyr LLP and provided a full release to Tyr LLP and Mr. Bunting.' The Company remains committed to a fair shareholder meeting process, in compliance with its constating documents and all applicable laws. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any impacts to MediPharm shareholders of the actions relating to the Applicants or Mr. McGee, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they in to access your portfolio

Person struck, killed by train: New Orleans police
Person struck, killed by train: New Orleans police

Yahoo

time12 hours ago

  • Yahoo

Person struck, killed by train: New Orleans police

NEW ORLEANS (WGNO) — The New Orleans Police Department is investigating after a person was struck and killed by a train Wednesday morning, June 11. Officers were alerted of a crash in the 3300 block of Earhart Boulevard of the B.W. Cooper neighborhood around 9:19 a.m. NOPD officials said investigators later determined that the crash happened on the Amtrak train tracks at the Norman C. Francis Boulevard overpass over Interstate 10. Controversy between councilman, Orleans Parish Sheriff's Office over alleged jail keys Responding officers learned the subject was struck and pronounced dead on the scene. NOPD officials said the case is being investigated as an unclassified death. No further details are available at this time. The Orleans Parish Coroner's Office will release the individual's identity after an autopsy is done and the family is a sword and champagne, Brennan's celebrates NOWFE in French Quarter FUELED Wellness + Nutrition | Seed oils: What you need to know How geography helped shape Jefferson Parish's growth Thune threatens to nix July 4 recess to finish work on Trump's 'big, beautiful bill' AI used to decide which JFK files remain classified: Gabbard Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

One hospitalized in Algiers shooting
One hospitalized in Algiers shooting

Yahoo

timea day ago

  • Yahoo

One hospitalized in Algiers shooting

ALGIERS, La. (WGNO) — A person has been hospitalized following a shooting that occurred in Algiers on Tuesday, June 10. According to the New Orleans Police Department, the shooting, which happened in the 3200 block of Memorial Park Drive, was first reported shortly before 12:15 p.m. Metairie man sentenced in 2024 child pornography case On scene, officers say they found one person who appeared to have been shot at least once. The victim was then taken to a hospital by New Orleans EMS. No further information was Oversight Republicans schedule interviews with former Biden aides Generator safety tips for hurricane season in Louisiana Senate Republican calls July 4 'false deadline' for megabill Man drowns in deadly rip current incident in Gulf County Bill could make federal minimum wage $15: The states paying less than that Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store